| 國立成功大學 |
2023 |
Safest-path planning approach for indoor fire evacuation
|
Shih, G.-R.;Tsai, P.-H. |
| 嘉南藥理大學 |
2009 |
Safety & Security in Tourism
|
EBSCO-HTC |
| 國家衛生研究院 |
2016-06 |
Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Siveke, J;Wang-Gillam, A;Hubner, R;Pant, S;Dragovich, T;Chung, V;Chang, D;Ross, P;Cooray, P;Tebbutt, N;Franke, F;Belanger, B;Dhindsa, N;de Jong, F;Mamlouk, K;Von Hoff, D |
| 國立臺灣大學 |
2012 |
Safety Analysis of FOLFOX4 Treatment in Colorectal Cancer Patients: A Comparison Between Two Asian Studies and Four Western Studies
|
Sugihara, Kenichi; Ohtsu, Atsushi; Shimada, Yasuhiro; Mizunuma, Nobuyuki; Lee, Po-Huang; de Gramont, Aimery; Goldberg, Richard M.; Rothenberg, Mace L.; Andre, Thierry; Brienza, Silvano; Gomi, Katsushige; 李伯皇 |
| 臺大學術典藏 |
2018-09-10T09:13:29Z |
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: A comparison between two Asian studies and four western studies
|
Sugihara, K. and Ohtsu, A. and Shimada, Y. and Mizunuma, N. and Lee, P.-H. and De Gramont, A. and Goldberg, R.M. and Rothenberg, M.L. and André, T. and Brienza, S. and Gomi, K.; PO-HUANG LEE |
| 臺大學術典藏 |
2020-11-19T03:19:35Z |
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: A comparison between two Asian studies and four western studies
|
Sugihara K.;Ohtsu A.;Shimada Y.;Mizunuma N.;Po-Huang Lee;De Gramont A.;Goldberg R.M.;Rothenberg M.L.;Andr? T.;Brienza S.;Gomi K.; Sugihara K.; Ohtsu A.; Shimada Y.; Mizunuma N.; PO-HUANG LEE; De Gramont A.; Goldberg R.M.; Rothenberg M.L.; Andr? T.; Brienza S.; Gomi K. |
| 淡江大學 |
2008-12 |
Safety Analysis of Level Crossing Surveillance Systems Using Fuzzy Petri Nets
|
Tao, Chi-chung; Lin,Tsung-chin |
| 臺大學術典藏 |
2022-09-06T08:33:56Z |
Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
|
Sheng, Wang-Huei; Wang, Chung-Cheng; Chu, Ching-Chi; Lin, Yueh-Juh; SUI-YUAN CHANG; Ieong, Si-Man; Chang, Shan-Chwen |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 國立成功大學 |
2021 |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque, A.;Chung, H.C.;Miguel, Miguel M.J.D.;Italiano, A.;MacHiels, J.-P.;Lin, C.-C.;Dhani, N.C.;Peeters, M.;Moreno, V.;Su, W.-C.;Chow, K.H.;Galvao, V.R.;Carlse, M.;Yu, D.;Szpurka, A.M.;Zhao, Y.;Schmidt, Schmidt S.L.;Gandhi, L.;Xu, Xu X.;Bang, Y.-J. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYnote-028 study
|
Hansen A.R.; Cheng J.D.; Thanigaimani P.; Saraf S.; CHIUN HSU; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study
|
Chiun Hsu;Lee S.-H.;Ejadi S.;Even C.;Cohen R.B.;Le Tourneau C.;Mehnert J.M.;Algazi A.;Van Brummelen E.M.J.;Saraf S.;Thanigaimani P.;Cheng J.D.;Hansen A.R.; Chiun Hsu; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Hansen A.R. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
|
Saraf S; Thanigaimani P; Cheng J.D; Keam B.; Mehnert J.M; Varga A; Brose M.S; Aggarwal R.R; Chia-Chi Lin; Prawira A; De Braud F; Tamura K; Doi T; Piha-Paul S.A; Gilbert J |
| 國立成功大學 |
2006-07 |
Safety and antiviral activity of pradefovir in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study
|
Lim, S. G.; Lee, K. S.; Chuang, W. L.; Hwang, S. G.; Cho, M.; Lai, M. Y.; Chao, Y. C.; Chang, Ting-Tsung; Han, K. H.; Lee, C. M.; Um, S. H.; Yeon, J. E.; Yang, S. S.; Teo, E. K.; Peng, C. Y.; Lin, H. H.; Yang, S. S.; Huo, T. I.; Nguyen, T.; Chen, T. Y.; Hu, K. Q.; Xu, Y.; Sullivan-Bolyai, J. Z. |
| 臺大學術典藏 |
2021-03-21T23:14:58Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik, Amita; Yap, Timothy A.; Chung, Hyun Cheol; de Miguel, Maria J.; Bang, Yung Jue; Chia-Chi Lin; Su, Wu Chou; Italiano, Antoine; Chow, Kay Hoong; Szpurka, Anna M.; Yu, Danni; Zhao, Yumin; Carlsen, Michelle; Schmidt, Shelly; Vangerow, Burkhard; Gandhi, Leena; Xu, Xiaojian; Bendell, Johanna |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 國立成功大學 |
2021 |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik, A.;Yap, T.A.;Chung, H.C.;de, Miguel M.J.;Bang, Y.-J.;Lin, C.-C.;Su, W.-C.;Italiano, A.;Chow, K.H.;Szpurka, A.M.;Yu, D.;Zhao, Y.;Carlsen, M.;Schmidt, Schmidt S.;Vangerow, B.;Gandhi, L.;Xu, Xu X.;Bendell, J. |
| 臺大學術典藏 |
2018-09-10T09:52:57Z |
Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
|
Wang, T.-S. and Tsai, T.-F.; TSEN-FANG TSAI |
| 臺大學術典藏 |
2020-10-22T07:28:05Z |
Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
|
Wang T.-S.;Tsen-Fang Tsai; Wang T.-S.; TSEN-FANG TSAI |
| 臺大學術典藏 |
2020-10-28T02:39:33Z |
Safety and Effectiveness of Hyaluronic Acid Fillers With Lidocaine for Full-Face Treatment in Asian Patients
|
Huang, She-Hung;Tsen-Fang Tsai; Huang, She-Hung; TSEN-FANG TSAI |
| 國立成功大學 |
2017 |
Safety and effectiveness of intravenous thrombolysis for acute ischemic stroke outside the coverage of National Health Insurance in Taiwan
|
Su, Y.-H.;Lin, H.-J.;Chen, Y.-W.;Tseng, M.-C.;Hsieh, Hsieh H.-C.;Chen, Chen C.-H.;Sung, Sung S.-F. |
| 國立成功大學 |
2021 |
Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: A feasibility study
|
Liu;Yi-Sheng;Lin;Xi-Zhang;Chen;Chiung-Yu;Chiu;Yen-Cheng;Kang;Jui-Wen;Tsai;Hung-Wen;Hung;Hui-Yu;Ho;Chi-Ming;Ou;Ming-Ching |
| 中國醫藥大學 |
2014-10 |
Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn’s Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
|
(Chen-Wang Chang);(Shu-Chen Wei);周仁偉(Jen-Wei Chou);(Tzu-Chi Hsu);(Chiao-Hsiung Chuang);(Ching-Pin Lin);(Wen-Hung Hsu);(Hsu-Heng Yen);(Jen-Kou Lin);(Yi-Jen Fang);(Horng-Yuan Wang);(Hung-Hsin Lin);(Deng Cheng Wu);(Yen Hsuan Ni);(Cheng-Yi Wang);(Jau-Min Wong)* |
| 國立成功大學 |
2000-08 |
Safety and efficacy of Alprostadil Sterile Powder (S. Po.. CAVERJECT (R)) in diabetic patients with erectile dysfunction
|
Tsai, Yuh-Shyan; Lin, Johnny Shinn-Nan; Lin, Yung-Ming |
| 臺大學術典藏 |
2022-03-28T02:45:55Z |
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
|
Diaz-Manera J.; Kishnani P.S.; Kushlaf H.; Ladha S.; Mozaffar T.; Straub V.; Toscano A.; van der Ploeg A.T.; Berger K.I.; Clemens P.R.; YIN-HSIU CHIEN; Day J.W.; Illarioshkin S.; Roberts M.; Attarian S.; Borges J.L.; Bouhour F.; Choi Y.C.; Erdem-Ozdamar S.; Goker-Alpan O.; Kostera-Pruszczyk A.; Haack K.A.; Hug C.; Huynh-Ba O.; Johnson J.; Thibault N.; Zhou T.; Dimachkie M.M.; Schoser B.; Behin A.; Boentert M.; Carvalho G.; Chahin N.; Charrow J.; Deegan P.; Durmus Tekce H.; Duval F.; Genge A.; Gutmann L.; Henderson R.D.; Hennermann J.B.; Hiwot T.; Hughes D.; Karaa A.; Karam C.; Kautzky-Willer A.; Komaki H.; Laforet P.; Longo N.; Malinova V.; Mar? R.; Maxit C.; Mengel E.; Moggio M.G.; Moln?r M.J.; Mongini T.E.; Nadaj-Pakleza A.; Nascimento Osorio A.; Noury J.-B.; Oliveira A.S.B.; Parman Y.; Pena L.; Remiche G.; Sciacco M.; Shieh P.B.; Smith C.; Stulnig T.; Taithe F.; Tard C.; Tarnopolsky M.; Vorgerd M.; Whitley C.; Young P.; Alonso-P?rez J.; Altemus P.; Aub?-Nathier A.-C.; Avelar J.B.; Bailey C.; Bekircan-Kurt C.E.; Billy J.; Boschi S.; Brown K.E.; Carrera Garcia L.; Chase L.; Cirne H.; Danjoux L.; Davion J.-B.; DeArmey S.; Fedotova E.; Gandolfo E.; Grosz Z.; Guellec D.; Guettsches A.-K.; Guglieri M.; Hatcher E.; Helms S.; Hufgard-Leitner M.; Klyushnikov S.A.; Langton J.; Linkov? L.; Mavroudakis N.; Mazurov? S.; Mori M.; M?ller-Miny L.; Musumeci O.; Nance C.S.; Natera-de Benito D.; Neel R.; Niizawa G.A.; Noll L.; Ortega E.; Pasnoor M.; Pautot V.; Potulska-Chromik A.; Pugliese A.; Questienne C.; Ramos Lopes M.; Reyes-Leiva D.; Riedl M.; Rugiero M.F.; Salort-Campana E.; Sgobbi Souza P.V.; Sole G.; Solera L.; Souto Lopes S.; Specht S.; Statland J.; Swenson A.; Tan C.Y.; Tizon S.; van der Beek N.A.M.E.; van Kooten H.A.; Wencel M.; Wenninger S.; Zagnoli F.; COMET Investigator Group |
